{"name":"Suzhou Kintor Pharmaceutical Inc,","slug":"suzhou-kintor-pharmaceutical-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"GT20029 Tincture","genericName":"GT20029 Tincture","slug":"gt20029-tincture","indication":"Other","status":"phase_2"},{"name":"GT90001","genericName":"GT90001","slug":"gt90001","indication":"Other","status":"phase_2"},{"name":"KX-826 1.0% BID","genericName":"KX-826 1.0% BID","slug":"kx-826-1-0-bid","indication":"Other","status":"phase_2"},{"name":"Proxalutamide","genericName":"Proxalutamide","slug":"proxalutamide","indication":"Other","status":"discontinued"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Proxalutamide (GT0918)","genericName":"Proxalutamide (GT0918)","slug":"proxalutamide-gt0918","indication":"Metastatic castration-resistant prostate cancer","status":"phase_3"}]},{"name":"Rare Disease","slug":"rare-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"KX-826-（5%） BID","genericName":"KX-826-（5%） BID","slug":"kx-826-5-bid","indication":"Androgenetic alopecia (male pattern baldness)","status":"phase_3"}]}],"pipeline":[{"name":"Proxalutamide (GT0918)","genericName":"Proxalutamide (GT0918)","slug":"proxalutamide-gt0918","phase":"phase_3","mechanism":"Proxalutamide is an androgen receptor antagonist.","indications":["Metastatic castration-resistant prostate cancer"],"catalyst":""},{"name":"GT20029 Tincture","genericName":"GT20029 Tincture","slug":"gt20029-tincture","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GT90001","genericName":"GT90001","slug":"gt90001","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"KX-826 1.0% BID","genericName":"KX-826 1.0% BID","slug":"kx-826-1-0-bid","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"KX-826-（5%） BID","genericName":"KX-826-（5%） BID","slug":"kx-826-5-bid","phase":"phase_3","mechanism":"KX-826 is a topical androgen receptor antagonist that inhibits DHT-mediated signaling in hair follicles to treat androgenetic alopecia.","indications":["Androgenetic alopecia (male pattern baldness)"],"catalyst":""},{"name":"Proxalutamide","genericName":"Proxalutamide","slug":"proxalutamide","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPY1JQREh3Ql9uSG1GbHdWVHByYUNOR3RUV1N1VThlVXhWMmFOVEtqekg0N1NaLTV2elluRURrSlg2RGNLc01DQzA5Mk5YWXFoNVJqX0NibDhFal85SWZDb1VFV3JtX0pJV2NHSTR6OFN0cF9JWmpUeHJxZ0FuRjdiOXN3V0Njemo1dUljbVpLdEozUW5CdjBoZw?oc=5","date":"2026-03-19","type":"trial","source":"BioWorld News","summary":"Kintor’s KX-826 meets phase III endpoints in alopecia - BioWorld News","headline":"Kintor’s KX-826 meets phase III endpoints in alopecia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigJBVV95cUxOLU9faXdZS09VSlhGTG5MTlp1OUlDTUVMMG54YmF2YUs2emVCMnhpRlo2QldGUHUtY25OSHpXN0NhTXlONXhtZ0tQcVdYVmswZDRuSjNHMndfSTV4LXBQZ2JoeFd4T3FrRl9zVlZEOXYwazZ5MDVwM2EtSVhQZlRGejh1Zlk4SjRqekpVNUpuUkR5ME5fYllzUnpITjRiYWxFVzg0cVhuamhzVUw4Nk1KN2NQZVR4V3hYT05fZXBpb2RWQlNMLUdLblFNSTZpTGFwVzQ0MGVNRC15T3hUSGZjRXZKZ2hubjYzWHpTZ2w2THdDVGZhS0k1TE9STlFtbkhfQjhxTnRpYllFZw?oc=5","date":"2026-03-12","type":"pipeline","source":"Minichart","summary":"Kintor Pharmaceutical Signs Strategic Cooperation with Fonow Medicine to Develop KT-939 Whitening and Freckle-Removing Cosmetics in China - Minichart","headline":"Kintor Pharmaceutical Signs Strategic Cooperation with Fonow Medicine to Develop KT-939 Whitening and Freckle-Removing C","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQbGtKLU1vcnBCaEFxV0dMSU1sbGJCaC05YmZ1dlFONVZjSHRsc3FzUUNQWi1SRHJLamVvdmpkWTJaNm9oYm8wNmpYOGNCMEpnbWptYTN5d0hUNVJVR3RoSENoQkdPbnB1NW1DY3N5eGlhdDlSNzMweVBfd181X19LUHNOa2NmSlhUYllXejhpekFfd3d6YnFfV0g5SXg?oc=5","date":"2025-05-15","type":"pipeline","source":"thebambooworks.com","summary":"Kintor Pharma shifts from cancer drugs to cosmetics as funds run low - thebambooworks.com","headline":"Kintor Pharma shifts from cancer drugs to cosmetics as funds run low","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQTEtmMVZHN3lNaVY2ZU5lN3hoQXdHT1BobzN1OXVUV3NzT2FzeXJrVmJ0RWt5c2J1amhoRGR1c1N0MWhtdU9PcVp5VXFQNzlTVTJORS1ENG1wR2ttUUNCODdPOC0tQkpUYU1Vc3A0bXRkSXZvSm42dktubDlQQV95cEZGVU9PSkNfemdZTFkyX0FOREZmb3g2anljWmI5RHZ0M2l3?oc=5","date":"2024-07-18","type":"pipeline","source":"thebambooworks.com","summary":"Kintor Pharma eyes regeneration with over-the-counter cosmetic treatments - thebambooworks.com","headline":"Kintor Pharma eyes regeneration with over-the-counter cosmetic treatments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQSjNjemdIVTZJbVpZTHVfcnpOOGNaajdyTkhpTzhJMVRHOUJPYWFBTjVWaUhyb1FzcEZCVmY1R0dkTUtSZGsyX2ZwS3BEZVVHTVNZQzIwdWNHRFVrbmpCdG5LN19YZmVsSEVMOEVBbWFoOENIczR1czNHakFHT0JBTGFzcXlSc21GdC1qendkcHNjVFFnT0dVRU9uYlNjYklNbDZCelJNR1hoTk1FUTdOemFUdjdIbngzcUxpSm5nLTc?oc=5","date":"2023-12-27","type":"pipeline","source":"西交利物浦大学","summary":"Alliances forged at summit to enhance regulation of China’s pharmaceutical industry - 西交利物浦大学","headline":"Alliances forged at summit to enhance regulation of China’s pharmaceutical industry - 西交利物浦大学","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxQdE00NTRaQk5pVTlrLTlTMWlZTUNtNm41S3oxRG54NGF3RWFFRlkyQ284Y2hqUklfOTVSQWcxSDZBUW9kbkdZUW5iQWhVSFgyQ1l1c0ZvX1FNaFpKQ1k1VzVIRHdmZjdodFVQN3B1d25OeGlfTVJFaFB6bzJLSTBvcG5Sd0hvX2JVNFlpVTZhMFprUVRoTEV4Z1dlOTFGeWtEazlFX2JuYWd4Wl9FZDVPUkVQSEpDcXBSQUpGeTE0ajhMY3poNTJYdk15MmJMZ1JRaThrbWlqOA?oc=5","date":"2019-08-21","type":"deal","source":"BioSpace","summary":"CMAB and Kintor Announce a New Comprehensive Collaboration to Develop and Manufacture the ALK-1 Monoclonal Antibody - BioSpace","headline":"CMAB and Kintor Announce a New Comprehensive Collaboration to Develop and Manufacture the ALK-1 Monoclonal Antibody","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNcF9OTHB3OTA5TGU0NmRrV0tReXpaX1VJdnZ0cExOU3IwQ3hqSVJ6RS1GbHZpOWxVdF9FeDhuMG9LVjdvRHNwU044UWgtM1owYmJzMDk4cTNGcmNfVW1KZnhOMTFiNVRnT3NjNDNreUFnTTlsLWNqcVZKeHUzU1pqXzVKTVZ1dFF6LUowV19KZm9jYzZkSzE3OWtNcVJDMGx4?oc=5","date":"2018-08-13","type":"pipeline","source":"macau daily times 澳門每日時報","summary":"Frontier, Kintor are said to join Hong Kong biotech listing wave - macau daily times 澳門每日時報","headline":"Frontier, Kintor are said to join Hong Kong biotech listing wave - macau daily times 澳門每日時報","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_3":2,"phase_2":3,"discontinued":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}